3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
2
Recruiting
2
Completed
2
Unknown
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
7
Peritoneal Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Colorectal Neoplasms
3
Carcinoma, Transitional Cell
3
Appendiceal Neoplasms
3
Urologic Neoplasms
2
Urogenital Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Pseudomyxoma Peritonei
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms
2
Anus Neoplasms
2
Uterine Neoplasms
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Sarcoma
1
Pleural Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Necrosis
1
Mediastinal Neoplasms
1
Male Urogenital Diseases
1
Gastrointestinal Neoplasms
1
Female Urogenital Diseases
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Blood Specimen Collection
38
pembrolizumab
36
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
18
Exercise
17
Carboplatin
16
Nivolumab
15
atezolizumab
14
Cisplatin
14
Drug Therapy
13
Paclitaxel
12
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
12
Trastuzumab
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Pemetrexed
9
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Mitomycin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT05874921
2025-02-28
uTRACT
UroGen Pharma Ltd.
Recruiting
400 enrolled